Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016444 | PMC |
| http://dx.doi.org/10.1093/infdis/jiab580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024).
Vaccine
August 2025
Department of Pharmacy, Henan Provincial People's Hospital, Zhengzhou, China. Electronic address:
Objectives: While the adjuvanted recombinant zoster vaccine (RZV) is preferred for herpes zoster (HZ) prevention due to its superior efficacy, emerging evidence suggests a potentially elevated reactogenicity risk relative to the live attenuated zoster vaccine (ZVL). This research aims to further assess the safety profiles of both vaccines, particularly the risk of serious adverse events following immunization (AEFIs) to provide more evidence for clinical decision.
Methods: Individual case safety reports from the Vaccine Adverse Event Reporting System (May 2006-December 2024) were analyzed.
Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial.
J Infect
August 2025
GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA. Electronic address:
Objectives: To assess HZ recurrence (primary objective), safety and immunogenicity of the recombinant zoster vaccine (RZV) in adults with prior HZ.
Methods: This phase 3, observer-blind, multi-country study (NCT04091451) enrolled participants ≥50 years with one resolved HZ episode >6 months prior, randomized 1:1 to receive two RZV or placebo doses 2 months apart. Recurrent HZ cases were confirmed by an algorithm comprising varicella-zoster virus-PCR and HZ adjudication determination.
Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network.
EClinicalMedicine
July 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Background: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster vaccine (RZV) in reducing both the incidence of HZ and all-cause mortality among individuals with RA.
Methods: We conducted a retrospective cohort study using data from the TriNetX U.
Recombinant Zoster Vaccine Use to Prevent Recurrent Shingles in an Adolescent Renal Transplant Recipient.
Cureus
May 2025
Department of Pediatrics, Stanford University, Stanford, USA.
Shingles, a reactivation of the varicella virus, is more common in immunosuppressed patients. Children with chronic or end-stage kidney disease may not respond effectively to live varicella vaccination, making it controversial post-transplant. Antiviral treatments for shingles can be nephrotoxic, and reducing immunosuppression to enhance immune responses may risk transplant rejection.
View Article and Find Full Text PDFPrevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Recipients-A Single-Center Analysis.
Infect Dis Rep
May 2025
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Banacha 1a Str., 02-097 Warsaw, Poland.
Background: Secondary immunodeficiencies in allo-HSCT (allogeneic hematopoietic stem cell transplantation) recipients increase the risk of viral reactivation, making vaccinations a vital issue. There is a paucity of data on the use of recombinant vaccine against herpes zoster (RZV) after allo-HSCT.
Methods: This analysis included 149 recipients of allo-HSCT, transplanted in 2012-2022, mainly due to hematological malignancies (>95%).